Clinical Trial Search

Primary: Mean Change in Cone Spacing in Arcminutes (Z Score) of 2 Baseline Values Were Compared With Measurements Obtained at Post-op Month 36 — 1.13; 0.85 Difference in change…

Primary: Rate of LOSS of 31 Hertz Cone Electroretinographic Function — 0.028; 0.022 log microvolts/year — p=0.30

Primary: Change in Dark Adaptation Rod Intercept Time (RIT) From Baseline in the Study Eye at the Treatment Completion Visit (Month 2 for Cohort 1 and Month 1 for Cohort 2)…

Primary: Height (Amplitude) of Multifocal ERG Signal — 2.859 nanovolt/degree^2 — p=<0.05

Primary: Sensitivity(mtmDR) — 90.48; 95.65; 95.19 percentage of true positives

Primary: Number of Subjects With Serious Adverse Events — 0; 0 Participants

Primary: Per Patient Referral Accuracy — 318 Participants

Primary: Change in Proteinuria at Week 24 From Baseline — 8.42; 7.67 g/g

Primary: Production of Anti-Retinal Pigment Epithelium (RPE) or Anti-retinal Antibody Formation in Neovascular ("Wet") Age-related Macular Degeneration Patients Compared to…

Primary: Change in Cystoid Macular Edema (CME) Based on Optical Coherence Tomography (OCT) Measurements in the Study Eye at 6 Months Compared to the Average of the Pre-treatment…

Primary: Number of Participant With Improvement in Foveal Thickness (Macular Fluid) as Measured by Optical Coherence Tomography (OCT) — 36 participants

Primary: Sensitivity Corrected for Enrichment — 87.2 percentage of true positives

Primary: The Mean Change in the Foveal Sensitivity of Matrix Frequency Doubling Perimetry (FDP) From Baseline in the Treated Group Compared to the Placebo Group — 2.80; 0.13 dB

Primary: Number of Participants With Progression of Diabetic Retinopathy of at Least 3 Stages on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale, or Development of…

Primary: Change in Dark Adaptation Rod Intercept Time (RIT) From Baseline in the Study Eye at the Treatment Completion Visit (Month 2 for Cohort 1 and Month 1 for Cohort 2)…

Primary: Rod Sensitivity Within the Central Retina as Measured on the Nidek MP-3S — 7; 20 Participants — p=<0.05

Primary: Adverse Event (AE) Reporting — 3; 3; 3; 2 Participants

Primary: Usability of the RetinaVue Hand-Held 100 Camera — 20; 116 Retinal Images

Primary: Percentage of Participants With Improvement in DRSS by ≥ 2 Steps at 48 Weeks of Treatment in the Study Eye — 0.0; 1.9 percentage of participants

Primary: Change in Dark Adaptation, Rod Intercept — 0.3; -0.3 minutes — p=.70

Primary: Proportion of Participants With >/= 2-Step Improvement in the Early Treatment Diabetic Retinopathy Study (ETDRS) DR Severity Scale (DRSS) From Baseline at Week 36…

Primary: Change in Humphrey Visual Fields - Total Sensitivity — 1.4; 16.8; -164.8; -66.7 dB

Primary: The Mean Percentage Change of the Area of the Patient's Neovascularization as Measured in Pixels by Optomap FA (Fluorescein Angiography) — -83.8; 52.6; 11.3; 55.4…

Primary: Rate of Retinal Attachment — 50; 42 Participants

Primary: Increase in Acid Sphingomyelinase (ASM) Expression and Activity in Bone Marrow-derived Endothelial Progenitor Cells (EPCs) — 0.2; 0.5 nM/hr

Primary: Change in Measurement in Central Macular Thickness Measured by Spectral Domain Optical Coherence Tomography( OCT) at One Month — -25.2; -29.9; -58.9 micrometers — p=0.04

Primary: Mean Duration of Definite Center of Macula-involved Diabetic Macular Edema (DME) — 1.72; 1.69 months per participant — p=0.969

Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA

Primary: Number of Participants Meeting the Primary Outcome Defined as Any of the Below Events Occurring During the 9 Weeks Following Administration, at Least Possibly Related to…

Primary: Changes in mRNA Expression in Blood of STAT3, PPAR-ɣ, and STC-1 at T0 — 4.19; 7.58; 6.43; 11.32 delta Ct (amplification cycles) — p=0.22